Stony Brook Experts

an online search tool for members of the media to identify experts at Stony Brook

Search experts:

or

Browse experts:

View all departments View all topics View all experts Close
Dr. Patricia K. Coyle Neurologist, Founder, Director, Multiple Sclerosis Comprehensive Care Center, Professor and Vice Chair (Clinical Affairs) of Neurology Neurology School of Medicine

Contact Information

T12-31 Health Sciences Center

Stony Brook, 11794

631/444-1809

Biography

Patricia Coyle is a recognized expert in nervous system immune-mediated and infectious disorders. She has been involved since medical school with patient care and research focused on multiple sclerosis (MS). Her particular areas of expertise include Lyme disease, cerebrospinal fluid, therapeutics, neuroimmunology, and gender issues. She is currently involved in a number of therapeutic trials testing new immunotherapies for MS, as well as studies addressing neurologic aspects of Lyme disease.

Education

  • Medical School, John Hopkins University
  • Residency, Johns Hopkins Hospital, Neurology
  • Residency, New York Hospital Cornell Medical Center, Internal Medicine
  • Fellowship, Johns Hopkins Hospital, Neuroimmunology/Virology

Research Grants

Award Start End Sponsor Type Amount Status
Protocol 031.0007 Prospective Open Label Tolerability and Safety Monitoring Study if Novatrone in a Selected Cohort of Multiple Sclerosis 2001-02-05T00:00:00 2008-08-08T00:00:00 Immunex Corporation Nonfederal 25700 Closed
Support for Discontinued Study - #100316 2002-08-01T00:00:00 2004-06-30T00:00:00 Bayer Corporation Nonfederal 2000 Closed
A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATM-027 IN PATIENTS WITH MULTIPLE SCLEROSIS .... 1999-08-06T00:00:00 2001-08-05T00:00:00 AstraZeneca LP Nonfederal 4982.4 Closed
Open-Label Three-Arm Study Camparing Low and High Dose CAMPATH (MABCAMPATH) and High-Dose Rebif in Patients with Early, Active Relapsing-Remitting Multiple Sclerosis 2003-04-09T00:00:00 2009-12-31T00:00:00 ILEX Pharmaceuticals, L.P. Nonfederal 229762.1 Closed
Assessment of Effect of Rebiject Mini in Tolerability of Rebif in Relapsing MS Patients 2002-02-13T00:00:00 2004-03-31T00:00:00 Serono Incorporated Nonfederal 31038 Closed
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy with Interferon-beta (IFN-B) Treatment in Multiple Sclerosis Subjects with Active Disease 2009-04-06T00:00:00 2011-09-23T00:00:00 EMD Serono Incorporated Nonfederal 4500 Closed
An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with Teriflunomide 7mg Once Daily 14mg Once Daily Versus Placebo in Patients with a 2008-10-06T00:00:00 2012-06-22T00:00:00 Sanofi-Aventis Nonfederal 5000 Closed
NEUROCRINE BIOSCIENCES: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF NBI5788 IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS 2003-11-01T00:00:00 2006-06-08T00:00:00 Pharmaceutical Research Associates Incorporated Nonfederal 42137 Closed
NEUROLOGIC ASPECTS OF LYME DISEASE IN NORTH AMERICA 1997-04-01T00:00:00 2003-03-31T00:00:00 National Inst of Neurological Disorders & Stroke Federal 5380084 Closed
A MULTI-NATIONAL,MULTI-CENTER,DOUBLEBLIND,PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY,TOLERABILITY & SAFETY OF... 1999-05-03T00:00:00 2004-02-12T00:00:00 Teva Neuroscience Inc Nonfederal 322254 Closed
International Multicenter, Phase III Study Patients with Relapsing-Remitting Multiple Sclerosis Comparing over Treatment Period of 104 Weeks 2004-04-22T00:00:00 2008-12-05T00:00:00 Berlex Laboratories Inc Nonfederal 233575 Closed
Quantitation of Blood Brain Barrier Permability in MS Lesion Development 2001-12-17T00:00:00 2004-09-30T00:00:00 Brookhaven Science Associates LLC Nonfederal 116029 Closed
AN OPEN LABEL RANDOMIZED MULTICENTER COMPARATIVE STUDY OF REBIF 44 MCG ADMINISTERED 3 TIMES PER WEEK BY SUBCUTANEOUS... 2000-01-12T00:00:00 2004-01-11T00:00:00 Serono Incorporated Nonfederal 488938 Closed
FIXED PRICE BALANCE ACCOUNT FOR DEPARTMENT OF NEUROLOGY 2003-01-01T00:00:00 2007-12-31T00:00:00 Multiple Sponsors Nonfederal 23260.99 Closed
A Randomized, Rater-blinded, Multicenter, Parallel-Group Study Comparing the Efficacy and Safety of Betaseron 250ug Subcutaneously Every Other Day with Avonex 30ug Intramuscularly Once per Week in Relapsing Remitting Multiple Sclerosis 2003-09-05T00:00:00 2007-06-06T00:00:00 Berlex Laboratories Inc Nonfederal 103068.69 Closed
Pharmacogenomics of Glatiramer Acetate: Genetic Basis of Responsiveness to Glatiramer Acetate in Multiple Sclerosis Patients 2002-08-16T00:00:00 2003-06-12T00:00:00 Teva Neuroscience Inc Nonfederal 1555.46 Closed
Study of Natalizumab in Combination with Glatiramer Acetate(GA) in Subjects with Relapsing-Remitting Multiple Sclerosis (MS) 2003-05-13T00:00:00 2005-04-11T00:00:00 Biogen Idec Nonfederal 63975 Closed
PROTOCOL NO. GA/7023 ORAL GLATIRAMER ACETATE IN RELAPSING REMITTING MULTIPLE SCLEROSIS 2000-02-25T00:00:00 2003-03-31T00:00:00 Teva Neuroscience Inc Nonfederal 59908.9 Closed
BAYER CORP: EFFECTS OF DIFFERENT DOSE REGIMENS OF IGIV-CHROMATOGRAPHY 91GIV-C, 10% TREATMENT ON RELAPSES IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS 2002-12-17T00:00:00 2006-10-26T00:00:00 PRA International Incorporated Nonfederal 132204 Closed
Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis: Protocol NIH/NINDS R U 01 NS45719-01A1 2004-12-28T00:00:00 2006-10-19T00:00:00 Mount Sinai School of Medicine Nonfederal 14840 Closed
AN OPEN LABEL STUDY EVALUATING THE ABILITY OF MULTIPLE SCLEROSIS PATIENTS ON CHRONIC REBIF 44 MCG TIW TREATMENT TO MOUNT AN IMMUNOLOGICAL RESPONSE TO INFLUENZA VACCINE 2003-10-03T00:00:00 2005-06-23T00:00:00 Serono Incorporated Nonfederal 42428 Closed
Safety/Tolerability of Betaseron 500mg Subcutaneously Every Other Day and Betaseron 250mg Every Other Day For Patients With Relapsing Remitting Multiple Sclerosis 2002-12-20T00:00:00 2009-06-27T00:00:00 Berlex Laboratories Inc Nonfederal 256676 Closed
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Four-Arm, Multicenter, Dose-Finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain 2012-03-02T00:00:00 2013-11-28T00:00:00 Avanir Pharmaceuticals Nonfederal 7500 Closed
Follow-up to a multi-center, prospective, open label tolerability and safety monitoring study of mitoxantrone hydrochloride(Novantrone) in a selected cohort of multiple sclerosis (MS) subjects 2011-11-21T00:00:00 2013-11-10T00:00:00 EMD Serono Incorporated Nonfederal 8262.5 Closed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects with a First Clinical Event at High Risk of Converting to MS 2010-08-16T00:00:00 2012-06-30T00:00:00 EMD Serono Incorporated Nonfederal 4500 Closed
Hyperbaric Oxygen Therapy for MS Relapse 2013-09-19T00:00:00 2015-07-09T00:00:00 Cure MS Foundation of New York Nonfederal 135240 Closed
PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY & EFFICACY OF 2 DOSES OF BETASERON IN PATIENTS WITH SECONDARY-PROG. MS 1996-04-18T00:00:00 2000-12-15T00:00:00 Berlex Laboratories Inc Nonfederal 1254404.75 Closed
Donation from National Multiple Sclerosis Society 2004-01-09T00:00:00 2015-12-31T00:00:00 National Multiple Sclerosis Society Nonfederal 151389.43 Closed
Phase II, Mutlicenter, Randomized, Parallel-group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy as Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients with 2009-02-02T00:00:00 2018-07-09T00:00:00 Genentech Incorporated Nonfederal 131828 Approved
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 1.25mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis 2010-01-08T00:00:00 2016-04-22T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 217328.49 Closed
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-Four Weeks 2010-02-01T00:00:00 2018-02-22T00:00:00 Actelion Clinical Research Incorporated Nonfederal 108448.75 Approved
A 12-month, randomized, rater & dose-blinded study to compare efficacy & safety of fingolimod administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing multiple sclerosis 2013-04-02T00:00:00 2018-08-03T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 61524.28 Approved
A Two-year Observational Study to Evaluate the Safety Profile of Fingolimod in Patients with Multiple Sclerosis who Switch from Natalizumab to Fingolimod 2013-11-13T00:00:00 2016-07-21T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 3000 Closed
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of AUBAGIO Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients 2014-05-13T00:00:00 2016-05-01T00:00:00 Sanofi US Services Incorporated Nonfederal 6375 Closed
Open-Label, Single-Arm Extension Study to the Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients..... 2014-08-14T00:00:00 2017-06-22T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 42938.02 Closed
A Phase 1b, Double-Blinded, Placebo-Controlled, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of PF-06342674 (RN168) in Subjects with Mulitple Sclerosis (MS) 2015-05-12T00:00:00 2016-05-11T00:00:00 Pfizer Incorporated Nonfederal 5000 Closed
Genentech: An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis who Have had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment 2016-02-27T00:00:00 2018-07-13T00:00:00 Pharmaceutical Research Associates Incorporated Nonfederal 7375 Approved
An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple Sclerosis 2017-01-26T00:00:00 2018-02-22T00:00:00 Genentech Incorporated Nonfederal 6625 Approved
A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate 2017-05-09T00:00:00 2018-05-09T00:00:00 Alkermes Incorporated Nonfederal 8190 Approved
Extended IL-7 Assay Protocol: For Detection of Proliferative and Cytokine Response Profiles, and Cross-Reactivities of Confirmed Antigen-Reactive Cells for the NBI-5788 Clinical Trial 2003-10-01T00:00:00 2005-03-10T00:00:00 University of California at San Francisco Nonfederal 56365 Approved
Fixed Price Balance Account for the Department of Neurology 2008-01-01T00:00:00 2018-06-30T00:00:00 Balance-Multiple Sponsors Nonsponsored 638842.49 Approved
Multicenter, Randomized, Double-Blind, Parallel-Group Extension Study AC-058B201 to Investigate the Long-Term Safety, Tolerability, and Efficacy of 10, 20 and 40 mg/day ACT-128800, and Oral S1P1 Receptor Agonist, in Patients with... 2011-04-18T00:00:00 2018-02-22T00:00:00 Actelion Clinical Research Incorporated Nonfederal 144998.35 Approved
Genentech: A Phase III, Multicentre, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis 2012-03-26T00:00:00 2018-04-12T00:00:00 PPD Development LP Nonfederal 204465.79 Approved
Genentech: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate The Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-la (Rebif) 2012-06-01T00:00:00 2018-05-10T00:00:00 Quintiles Incorporated Nonfederal 213850 Approved
Clinical Research Offset Award for Neurology 2012-09-01T00:00:00 2018-08-31T00:00:00 Multiple Sponsors - Nonsponsored Nonsponsored 1 Approved
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects with Secondary Progressive Multiple Sclerosis 2013-02-14T00:00:00 2018-05-25T00:00:00 Opexa Therapeutics Nonfederal 210883.5 Approved
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Variable Treatment Durations Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients with Secondary Progressive Multiple Sclerosis 2013-09-06T00:00:00 2018-02-15T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 304565.5 Approved
A Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-66) in Subjects with Progressive Multiple Sclerosis 2014-03-19T00:00:00 2017-03-18T00:00:00 Massachusetts General Hospital Nonfederal 108387.65 Approved
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACED/Fingolimod to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS) 2015-07-30T00:00:00 2017-04-30T00:00:00 Biogen Idec Nonfederal 7225 Closed
A Phase 3 Open Label Study to Evaluate the Long-Term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis 2016-11-29T00:00:00 2018-07-31T00:00:00 Alkermes Incorporated Nonfederal 26216.51 Approved
A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab versus Teriflunomide in Patients with Relapsing Multiple Sclerosis 2016-12-05T00:00:00 2018-10-25T00:00:00 Novartis Pharmaceuticals Corporation Nonfederal 11250 Approved
MEDDAY: Effect of MD1003 in Progressive Multiple Sclerosis: A Randomized Double-Blind Placebo Controlled Study 2017-01-23T00:00:00 2018-12-04T00:00:00 Parexel International LLC Nonfederal 11698.5 Approved
Funds for Olga Syritsyna: Multiple Sclerosis Clinical Care Physician Fellowship 2017-11-01T00:00:00 2018-10-31T00:00:00 Biogen MA Incorporated Nonfederal 90000 Approved

Publications

  1. Author Article Archives of Neurology Pediatric Multiple Sclerosis: Just Like Their Elders? 2011 68 4 419 - 421
  2. Author Article PLoS ONE Establishing the Proteome of Normal Human Cerebrospinal Fluid 2010 5 6
  3. Author Article Neurology Rapid disease course in African Americans with multiple sclerosis 2010 75 3 217 - 223
  4. Author Article Women's Health Gender issues in multiple sclerosis: an update 2010 6 6 797 - 820
  5. Author Article Multiple Sclerosis Optimizing Outcomes in Multiple Sclerosis - A Consensus Initiative 2009 15
  6. Author Article Annals of Indian Academy of Neurology Disease-modifying agents in multiple sclerosis 2009 12 4 273
  7. Author Article Behavioural Brain Research Maternal dietary zinc supplementation prevents aberrant behaviour in an object recognition task in mice offspring exposed to LPS in early pregnancy 2009 197 1 210 - 218
  8. Author Article Current Opinion in Neurology Existing therapies for multiple sclerosis offer proven efficacy and safety 2009 22
  9. Author Article Multiple Sclerosis Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy 2009 15
  10. Author Article Multiple Sclerosis Clinical efficacy and benefit of natalizumab 2009 15
  11. Author Article Lancet Neurology Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial 2008 7 10 903 - 914
  12. Author Article Journal of Neurology Switching algorithms: from one immunomodulatory agent to another 2008 255 0 44
  13. Author Article Neurology Early treatment of multiple sclerosis to prevent neurologic damage 2008 71
  14. Author Article Clinical Therapeutics Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 µg QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study 2008 30 6 1102 - 1112
  15. Author Article Annals of Neurology Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial 2007 61 1 14 - 24
  16. Author Article Journal of the Neurological Sciences Relapses matter: The costs & consequences of multiple sclerosis relapses 2007 256
  17. Author Article Neurology Evidence-based medicine and clinical trials 2007 68
  18. Author Article Archives of Neurology High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis 2006 63 10 1388 - 1393
  19. Author Article Multiple Sclerosis A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif<SUP>r</SUP>) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis 2005 11 5 585 - 591
  20. Author Article Journal of Neuroimmunology Increased serum neopterin levels in adults with Down syndrome 2005 164 1 129 - 133
  21. Author Article Neurologic Clinics Gender issues 2005 23 1 39 - 60
  22. Author Article Journal of the Neurological Sciences Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial 2005 239 1 67 - 74
  23. Author Article Journal of Neuro-Ophthalmology Reactive Lyme Serology in Optic Neuritis 2005 25 2 71 - 82
  24. Author Article Multiple Sclerosis Multiple sclerosis gender issues: clinical practices of women neurologists 2004 10 5 582 - 588
  25. Author Article Journal of Clinical Microbiology Preferential Presence of Decorin-Binding Protein B (BBA25) and BBA50 Antibodies in Cerebrospinal Fluid of Patients with Neurologic Lyme Disease 2004 42 3 1243 - 1246
  26. Author Article Acta Neurologica Scandinavica Intrathecal production of measles-specific IgA in subacute sclerosing panencephalitis 1997 96 2 97 - 100

Video